Traumatic brain injury (TBI) encompasses primary brain damage inflicted immediately at the time of impact, and secondary damage involving cellular and molecular alterations progressing over a prolonged time post‑trauma. Despite a large number of previous successful preclinical proof-of-concept studies, some of which have progressed to failed clinical trials, there are no pharmacotherapies in clinical use that can improve structural and functional recovery from TBI. Early identification of patients at risk of developing the long-term comorbidities is a key aspect for future drug trials testing novel recovery-enhancing and anti‑epileptogenic treatments for TBI. We hypothesize that circulating miRNAs can diagnose ongoing epileptogenesis and serve as prognostic biomarkers for post-traumatic epilepsy and behavioral and cognitive co-morbidities in a clinically relevant rat model of TBI. Described research is part of the EPITARGET Consortium.